Dapagliflozin Metabolism, UGT1A9 Pathway and FDA Label
Dapagliflozin is metabolized mainly via UGT1A9 glucuronidation, per the FDA label. Covers approved indications, 10 mg dosing, and global regulatory status.
Dapagliflozin: Regulatory History
3 source-based articles maintained by the HealthRX.com Editorial Team.
3articles
2topic areas covered
Jan 10, 2025latest review
Dapagliflozin: Regulatory History library
Showing 3 of 3 clinical reviews.
Farxiga Prescribing Information: 2020-2026 Label Updates
Farxiga's FDA label expanded three times since 2020, adding HFrEF, chronic kidney disease, and broader heart failure indications. See the full regulatory timeline.
How Long Has Farxiga Been on the Market? Since 2014
Farxiga won FDA approval January 8, 2014 for type 2 diabetes, then added heart failure (2020) and chronic kidney disease (2021) indications.